IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions…
Search
Tag: imaavy
